Novartis Looks To Recent Launches To Bolster Diovan Against Generic Onslaught
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss pharma predicts hypertension blockbuster still will earn $2 billion annually outside the U.S. after patent expirations.